142 related articles for article (PubMed ID: 24605823)
1. Aberrant promoter methylation and silencing of RASSF2A gene in cervical cancer.
Zhang X; Ma Y; Wu Y; Lin L; Ma X; Zhang Y
J Obstet Gynaecol Res; 2014 May; 40(5):1375-81. PubMed ID: 24605823
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.
Zhang Z; Sun D; Van do N; Tang A; Hu L; Huang G
Int J Cancer; 2007 Jan; 120(1):32-8. PubMed ID: 17013896
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
[TBL] [Abstract][Full Text] [Related]
5. IGSF4 promoter methylation and expression silencing in human cervical cancer.
Li J; Zhang Z; Bidder M; Funk MC; Nguyen L; Goodfellow PJ; Rader JS
Gynecol Oncol; 2005 Jan; 96(1):150-8. PubMed ID: 15589594
[TBL] [Abstract][Full Text] [Related]
6. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.
Hesson LB; Wilson R; Morton D; Adams C; Walker M; Maher ER; Latif F
Oncogene; 2005 Jun; 24(24):3987-94. PubMed ID: 15806169
[TBL] [Abstract][Full Text] [Related]
7. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
[TBL] [Abstract][Full Text] [Related]
8. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.
Park HW; Kang HC; Kim IJ; Jang SG; Kim K; Yoon HJ; Jeong SY; Park JG
Int J Cancer; 2007 Jan; 120(1):7-12. PubMed ID: 17013898
[TBL] [Abstract][Full Text] [Related]
9. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.
Liao X; Siu MK; Chan KY; Wong ES; Ngan HY; Chan QK; Li AS; Khoo US; Cheung AN
Int J Cancer; 2008 Jul; 123(2):296-302. PubMed ID: 18404674
[TBL] [Abstract][Full Text] [Related]
11. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
[TBL] [Abstract][Full Text] [Related]
12. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.
Song Y; Zhang C
Cancer Chemother Pharmacol; 2009 Mar; 63(4):605-13. PubMed ID: 18521605
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Hypermethylation of SALL3 with HPV Involvement Contributes to the Carcinogenesis of Cervical Cancer.
Wei X; Zhang S; Cao D; Zhao M; Zhang Q; Zhao J; Yang T; Pei M; Wang L; Li Y; Yang X
PLoS One; 2015; 10(12):e0145700. PubMed ID: 26697877
[TBL] [Abstract][Full Text] [Related]
14. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of SOX11 promotes the progression of cervical cancer in vitro and in vivo.
Li X; Wu X; Li Y; Cui Y; Tian R; Singh N; Ding M; Yang Y; Gao Y
Oncol Rep; 2019 Apr; 41(4):2351-2360. PubMed ID: 30720133
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis.
Yang WT; Zheng PS
PLoS One; 2014; 9(2):e88827. PubMed ID: 24551169
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer.
Maruyama R; Akino K; Toyota M; Suzuki H; Imai T; Ohe-Toyota M; Yamamoto E; Nojima M; Fujikane T; Sasaki Y; Yamashita T; Watanabe Y; Hiratsuka H; Hirata K; Itoh F; Imai K; Shinomura Y; Tokino T
Carcinogenesis; 2008 Jul; 29(7):1312-8. PubMed ID: 18310659
[TBL] [Abstract][Full Text] [Related]
19. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers.
Xie XM; Zhang ZY; Yang LH; Yang DL; Tang N; Zhao HY; Xu HT; Li QC; Wang EH
Int J Oncol; 2013 Nov; 43(5):1636-42. PubMed ID: 24002585
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of EZH2 reactivates RASSF2A by reversal of promoter methylation in breast cancer cells.
Yu P; Guo Y; Yusufu M; Liu Z; Wang S; Yin X; Peng G; Wang L; Zhao X; Guo H; Huang T; Liu C
Cell Biol Int; 2016 Oct; 40(10):1062-70. PubMed ID: 27436059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
